Beaulieu JM, Gainetdinov RR (2011) The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev 63(1):182–217. https://doi.org/10.1124/pr.110.002642
Luthra PM, Kumar JBS (2012) Plausible improvements for selective targeting of dopamine receptors in therapy of Parkinson’s disease. Mini-Rev Med Chem 12(14):1556–1564. https://doi.org/10.2174/138955712803832645
Poewe W (2009) Treatments for Parkinson disease-past achievements and current clinical needs. Neurology 72 (7 SUPPL. 2):S65-S73. https://doi.org/10.1212/WNL.0b013e31819908ce
[+]
Beaulieu JM, Gainetdinov RR (2011) The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev 63(1):182–217. https://doi.org/10.1124/pr.110.002642
Luthra PM, Kumar JBS (2012) Plausible improvements for selective targeting of dopamine receptors in therapy of Parkinson’s disease. Mini-Rev Med Chem 12(14):1556–1564. https://doi.org/10.2174/138955712803832645
Poewe W (2009) Treatments for Parkinson disease-past achievements and current clinical needs. Neurology 72 (7 SUPPL. 2):S65-S73. https://doi.org/10.1212/WNL.0b013e31819908ce
Seeman P, Watanabe M, Grigoriadis D (1985) Dopamine D2 receptor binding sites for agonists: a tetrahedral model. Mol Pharmacol 28(5):391–399
McDonald WM, Sibley DR, Kilpatrick BF, Caron MG (1984) Dopaminergic inhibition of adenylate cyclase correlates with high affinity agonist binding to anterior pituitary D2 dopamine receptors. Mol Cell Endocrinol 36(3):201–209. https://doi.org/10.1016/0303-7207(84)90037-6
Mottola DM, Laiter S, Watts VJ, Tropsha A, Wyrick SD, Nichols DE, Mailman RB (1996) Conformational analysis of D1 dopamine receptor agonists: pharmacophore assessment and receptor mapping. J Med Chem 39(1):285–296. https://doi.org/10.1021/jm9502100
Alkorta I, Villar HO (1993) Considerations on the recognition of the D1 receptor by agonists. J Comput Aided Mol Des 7(6):659–670. https://doi.org/10.1007/BF00125324
Cueva JP, Giorgioni G, Grubbs RA, Chemel BR, Watts VJ, Nichols DE (2006) Trans-2,3-dihydroxy-6a,7,8,12b-tetrahydro-6H-chromeno[3,4-c]isoquinoline: synthesis, resolution, and preliminary pharmacological characterization of a new dopamine D1 receptor full agonist. J Med Chem 49(23):6848–6857. https://doi.org/10.1021/jm0604979
Negash K, Nichols DE, Watts VJ, Mailman RB (1997) Further definition of the D1 dopamine receptor pharmacophore: synthesis of trans-6,6a,7,8,9,13b-hexahydro-5h-benzo[d]naphth[2,1-b]azepines as rigid analogues of β-phenyldopamine. J Med Chem 40(14):2140–2147. https://doi.org/10.1021/jm970157a
Pettersson I, Liljefors T (1987) Structure-activity relationships for apomorphine congeners. Conformational energies vs. biological activities. J Comput Aided Mol Des 1(2):143–152. https://doi.org/10.1007/BF01676958
Tonani R, Dunbar Jr J, Edmonston B, Marshall GR (1987) Computer-aided molecular modeling of a D2-agonist dopamine pharmacophore. J Comput Aided Mol Des 1(2):121–132. https://doi.org/10.1007/BF01676956
Mewshaw RE, Kavanagh J, Stack G, Marquis KL, Shi X, Kagan MZ, Webb MB, Katz AH, Park A, Kang YH, Abou-Gharbia M, Scerni R, Wasik T, Cortes-Burgos L, Spangler T, Brennan JA, Piesla M, Mazandargmi H, Cockett MI, Ochalski R, Coupet J, Andree TH (1997) New generation dopaminergic agents. 1. Discovery of a novel scaffold which embraces the D2 agonist pharmacophore. Structure-activity relationships of a series of 2-(aminomethyl)chromans. J Med Chem 40(26):4235–4256. https://doi.org/10.1021/jm9703653
Chidester CG, Lin CH, Lahti RA, Haadsma-Svensson SR, Smith MW (1993) Comparison of 5-HT1A and dopamine D2 pharmacophores. X-ray structures and affinities of conformationally constrained ligands. J Med Chem 36(10):1301–1315
Alkorta I, Villar HO (1994) Molecular electrostatic potential of d1 and d2 dopamine agonists. J Med Chem 37(1):210–213
Wilcox RE, Tseng T, Brusniak MYK, Ginsburg B, Pearlman RS, Teeter M, Durand C, Starr S, Neve KA (1998) CoMFA-based prediction of agonist affinities at recombinant D1 vs D2 dopamine receptors. J Med Chem 41(22):4385–4399. https://doi.org/10.1021/jm9800292
El Aouad N, Berenguer I, Romero V, Marín P, Serrano A, Andujar S, Suvire F, Bermejo A, Ivorra MD, Enriz RD, Cabedo N, Cortes D (2009) Structure-activity relationship of dopaminergic halogenated 1-benzyl-tetrahydroisoquinoline derivatives. Eur J Med Chem 44(11):4616–4621. https://doi.org/10.1016/j.ejmech.2009.06.033
Berenguer I, Aouad NE, Andujar S, Romero V, Suvire F, Freret T, Bermejo A, Ivorra MD, Enriz RD, Boulouard M, Cabedo N, Cortes D (2009) Tetrahydroisoquinolines as dopaminergic ligands: 1-butyl-7-chloro-6-hydroxy-tetrahydroisoquinoline, a new compound with antidepressant-like activity in mice. Bioorg Med Chem 17(14):4968–4980. https://doi.org/10.1016/j.bmc.2009.05.079
Andujar S, Suvire F, Berenguer I, Cabedo N, Marin P, Moreno L, Dolores Ivorra M, Cortes D, Enriz RD (2012) Tetrahydroisoquinolines acting as dopaminergic ligands. A molecular modeling study using MD simulations and QM calculations. J Mol Model 18(2):419–431. https://doi.org/10.1007/s00894-011-1061-0
Angelina E, Andujar S, Tosso RD, Enriz RD, Peruchena N (2014) Non-covalent interactions in receptor–ligand complexes. A study based on the electron charge density. J Phys Org Chem 27:128–134
Parraga J, Cabedo N, Andujar S, Piqueras L, Moreno L, Galan A, Angelina E, Enriz RD, Ivorra MD, Sanz MJ, Cortes D (2013) 2,3,9- and 2,3,11-trisubstituted tetrahydroprotoberberines as D2 dopaminergic ligands. Eur J Med Chem 68:150–166
Andujar SA, de Angel BM, Charris JE, Israel A, Suarez-Roca H, Lopez SE, Garrido MR, Cabrera EV, Visbal G, Rosales C, Suvire FD, Enriz RD, Angel-Guio JE (2008) Synthesis, dopaminergic profile, and molecular dynamics calculations of N-aralkyl substituted 2-aminoindans. Bioorg Med Chem 16(6):3233–3244
Párraga J, Andujar SA, Rojas S, Gutierrez LJ, El Aouad N, Sanz MJ, Enriz RD, Cabedo N, Cortes D (2016) Dopaminergic isoquinolines with hexahydrocyclopenta[ij]-isoquinolines as D2−like selective ligands. Eur J Med Chem 122:27-42. https://doi.org/10.1016/j.ejmech.2016.06.009
Galán A, Moreno L, Párraga J, Serrano Á, Sanz MJ, Cortes D, Cabedo N (2013) Novel isoquinoline derivatives as antimicrobial agents. Bioorg Med Chem 21(11):3221–3230. https://doi.org/10.1016/j.bmc.2013.03.042
Malo M, Brive L, Luthman K, Svensson P (2010) Selective pharmacophore models of dopamine D1 and D2 full agonists based on extended pharmacophore features. ChemMedChem 5(2):232–246. https://doi.org/10.1002/cmdc.200900398
Lan H, DuRand CJ, Teeter MM, Neve KA (2006) Structural determinants of pharmacological specificity between D 1 and D2 dopamine receptors. Mol Pharmacol 69(1):185–194. https://doi.org/10.1124/mol.105.017244
Neve KA, Cumbay MG, Thompson KR, Yang R, Buck DC, Watts VJ, Durand CJ, Teeter MM (2001) Modeling and mutational analysis of a putative sodium-binding pocket on the dopamine D2 receptor. Mol Pharmacol 60(2):373–381
Kalani MYS, Vaidehi N, Hall SE, Trabanino RJ, Freddolino PL, Kalani MA, Floriano WB, Wai Tak Kam V, Goddard Iii WA (2012) The predicted 3D structure of the human D2 dopamine receptor and the binding site and binding affinities for agonists and antagonists. Proc Natl Acad Sci USA 101:3815–3820
Becker OM, Marantz Y, Shacham S, Inbal B, Heifetz A, Kalid O, Bar-Haim S, Warshaviak D, Fichman M, Noiman S (2004) G protein-coupled receptors: in silico, drug discovery in 3D. Proc Natl Acad Sci USA 101(31):11304–11309. https://doi.org/10.1073/pnas.0401862101
Micheli F, Bonanomi G, Blaney FE, Braggio S, Capelli AM, Checchia A, Curcuruto O, Damiani F, Di Fabio R, Donati D, Gentile G, Gribble A, Hamprecht D, Tedesco G, Terreni S, Tarsi L, Lightfoot A, Stemp G, MacDonald G, Smith A, Pecoraro M, Petrone M, Perini O, Piner J, Rossi T, Worby A, Pilla M, Valerio E, Griffante C, Mugnaini M, Wood M, Scott C, Andreoli M, Lacroix L, Schwarz A, Gozzi A, Bifone A, Ashby Jr CR, Hagan JJ, Heidbreder C (2007) 1,2,4-Triazol-3-yl-thiopropyl-tetrahydrobenzazepines: a series of potent and selective dopamine D3 receptor antagonists. J Med Chem 50(21):5076–5089. https://doi.org/10.1021/jm0705612
Párraga J, Cabedo N, Andujar S, Piqueras L, Moreno L, Galán A, Angelina E, Enriz RD, Ivorra MD, Sanz MJ, Cortes D (2013) 2,3,9- and 2,3,11-Trisubstituted tetrahydroprotoberberines as D2 dopaminergic ligands. Eur J Med Chem. 68:150-166. https://doi.org/10.1016/j.ejmech.2013.07.036
Angelina E, Andujar S, Moreno L, Garibotto F, Párraga J, Peruchena N, Cabedo N, Villecco M, Cortes D, Enriz RD (2015) 3-chlorotyramine acting as ligand of the D2 dopamine receptor. Molecular modeling, synthesis and D2 receptor affinity. Molec Inform 34 (1):28-43. https://doi.org/10.1002/minf.201400093
Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, Olson AJ (2009) AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem 30(16):2785–2791
Lindorff-Larsen K, Piana S, Palmo K, Maragakis P, Klepeis JL, Dror RO, Shaw DE (2010) Improved side-chain torsion potentials for the amber ff99SB protein force field. Proteins 78(8):1950–1958. https://doi.org/10.1002/prot.22711
Wang J, Wolf RM, Caldwell JW, Kollman PA, Case DA (2004) Development and testing of a general amber force field. J Comput Chem 25(9):1157–1174
Case DA, Darden TA, Cheatham III TE, Simmerling CL, Wang J, Duke RE, Luo R, Walker RC, Zhang W, Merz KM, Roberts B, Hayik S, Roitberg A, Seabra G, Swails J, Goetz AW, Kolossváry I, Wong KF, Paesani F, Vanicek J, Wolf RM, Liu J, Wu X, Brozell SR, Steinbrecher T, Gohlke H, Cai Q, Ye X, Wang J, Hsieh M-J, Cui G, Roe DR, Mathews DH, Seetin MG, Salomon-Ferrer R, Sagui C, Babin V, Luchko T, Gusarov S, Kovalenko A, Kollman PA (2012) AMBER12. University of California, San Francisco
Ryckaert JP, Ciccotti G, Berendsen HJC (1977) Numerical integration of the cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes. J Comput Phys 23(3):327–341. https://doi.org/10.1016/0021-9991(77)90098-5
Izaguirre JA, Catarello DP, Wozniak JM, Skeel RD (2001) Langevin stabilization of molecular dynamics. J Chem Phys 114(5):2090–2098. https://doi.org/10.1063/1.1332996
Essmann U, Perera L, Berkowitz M, Darden T, Lee H, Pedersen L (1995) A smooth particle mesh Ewald method. J Chem Phys 103:8577–8593
Hou T, Li N, Li Y, Wang W (2012) Characterization of domain-peptide interaction interface: prediction of SH3 domain-mediated protein-protein interaction network in yeast by generic structure-based models. J Proteome Res 11(5):2982–2995
Gohlke H, Kiel C, Case DA (2003) Insights into protein-protein binding by binding free energy calculation and free energy decomposition for the Ras-Raf and Ras-RalGDS complexes. J Mol Biol 330(4):891–913
Frisch MJ, Trucks GW, Schlegel HB, Scuseria GE, Robb MA, Cheeseman JR, Scalmani G, Barone V, Mennucci B, Petersson GA, Nakatsuji H, Caricato M, Li X, Hratchian HP, Izmaylov AF, Bloino J, Zheng G, Sonnenberg JL, Hada M, Ehara M, Toyota K, Fukuda R, Hasegawa J, Ishida M, Nakajima T, Honda Y, Kitao O, Nakai H, Vreven T, Montgomery JA, Jr., Peralta JE, Ogliaro F, Bearpark M, Heyd JJ, Brothers E, Kudin KN, Staroverov VN, Kobayashi R, Normand J, Raghavachari K, Rendell A, Burant JC, Iyengar SS, Tomasi J, Cossi M, Rega N, Millam JM, Klene M, Knox JE, Cross JB, Bakken V, Adamo C, Jaramillo J, Gomperts R, Stratmann RE, Yazyev O, Austin AJ, Cammi R, Pomelli C, Ochterski JW, Martin RL, Morokuma K, Zakrzewski VG, Voth GA, Salvador P, Dannenberg JJ, Dapprich S, Daniels AD, Farkas Ö, Foresman JB, Ortiz JV, Cioslowski J, Fox DJ (2009) Gaussian 09 revision D.01. Gaussian Inc, Wallingford
Bader RFW (1994) Atoms in molecules: a quantum theory. Clarendon, Oxford
Lu T, Chen F (2012) Multiwfn: a multifunctional wavefunction analyzer. J Comput Chem 33(5):580–592
Case DA, Cheatham Iii TE, Darden T, Gohlke H, Luo R, Merz Jr KM, Onufriev A, Simmerling C, Wang B, Woods RJ (2005) The amber biomolecular simulation programs. J Comput Chem 26(16):1668–1688. https://doi.org/10.1002/jcc.20290
Angel Guio JE, Santiago A, Rossi R, Migliore de Angel B, Barolo S, Andujar S, Hernandez V, Rosales C, Charris JE, Suarez-Roca H, Israel A, Ramirez MM, Ortega J, Cano NH, Enriz RD (2011) Synthesis and preliminary pharmacological evaluation of methoxilated indoles with possible dopaminergic central action. Lat Am J Pharm 30(10):1934
Andujar SA, Tosso RD, Suvire FD, Angelina E, Peruchena N, Cabedo N, Cortes D, Enriz RD (2012) Searching the “biologically relevant” conformation of dopamine: a computational approach. J Chem Inf Model 52(1):99–112. https://doi.org/10.1021/ci2004225
Sealfon SC, Chi L, Ebersole BJ, Rodic V, Zhang D, Ballesteros JA, Weinstein H (1995) Related contribution of specific helix 2 and 7 residues to conformational activation of the serotonin 5-HT2A receptor. J Biol Chem 270(28):16683–16688
Trzaskowski B, Latek D, Yuan S, Ghoshdastider U, Debinski A, Filipek S (2012) Action of molecular switches in GPCRs - theoretical and experimental studies. Curr Med Chem 19(8):1090–1109. https://doi.org/10.2174/092986712799320556
Tosso RD, Andujar SA, Gutierrez L, Angelina E, Rodriguez R, Nogueras M, Baldoni H, Suvire FD, Cobo J, Enriz RD (2013) Molecular modeling study of dihydrofolate reductase inhibitors. Molecular dynamics simulations, quantum mechanical calculations, and experimental corroboration. J Chem Inf Model 53(8):2018–2032
Ortiz JE, Pigni NB, Andujar SA, Roitman G, Suvire FD, Enriz RD, Tapia A, Bastida J, Feresin GE (2016) Alkaloids from Hippeastrum Argentinum and their cholinesterase-inhibitory activities: an in vitro and in Silico study. J Nat Prod 79(5):1241–1248. https://doi.org/10.1021/acs.jnatprod.5b00785
Luchi AM, Angelina EL, Andujar SA, Enriz RD, Peruchena NM (2016) Halogen bonding in biological context: a computational study of D2 dopamine receptor. J Phys Org Chem 29 (11):645-655. https://doi.org/10.1002/poc.3586
[-]
![[Cerrado]](/themes/UPV/images/candado.png)
